Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Brief Summary: This is an open-label, single arm, multi-center, pilot study of Nivolumab in pediatric patients with recurrent or refractory hypermutant malignancies aged 12 months to 18 years of age. This study is to assess clinical and radiological benefits of treatment with Nivolumab in children with hypermutated cancers, including those with bMMRD syndrome. It is our expectation that patients with bMMRD syndrome will account for the majority of patients enrolled on this study.